Please login to the form below

Not currently logged in

Pfizer launches Latin American vaccine education campaign

Public-facing pneumococcal disease campaign will cover 14 countries in the region

Pfizer is working with Miami-based communications agency Jeffrey Group on a public health education campaign to raise awareness of pneumococcal disease in 14 Latin American countries.

The US pharma company aims to educate Latin Americans about vaccines for adults over the age of 50 suffering from pneumococcal disease.

"With approximately 125,000 Latin Americans over the age of 50 dying each year from pneumococcal disease, we felt it was critical to lead an aggressive awareness campaign to help educate the public about their prevention options," said Mark Partridge, Pfizer's regional marketing head of vaccines for Latin America.

"With that in mind, it was just as critical to choose the right partner with demonstrated healthcare expertise in the complex Latin American regulatory environment."

Headquartered in Miami, the Jeffrey Group has offices in New York, Mexico City, Sao Paulo and Buenos Aires and specialises in helping businesses engage Latin audiences.

The campaign will focuses on awareness and prevention, taking an unbranded approach and using a trilingual website, social media management, testimonial videos, key opinion leader outreach, consumer events, community outreach and traditional media relations.

22nd August 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...